Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Valeant Pharmaceuticals (VRX) PT Lowered to $18 at Jefferies
March 1, 2017 7:46 AM ESTJefferies lowered its price target on Valeant Pharmaceuticals (NYSE: VRX) to $18.00 (from $22.00) while maintaining a Buy rating following Q4 result and outlook.
Analyst David Steinberg commented, "Q4 EPS of $1.26 was ~5% ahead of cons with revs just topping guidance ($2.28-2.38B) at $2.40B. More importantly,... More
Valeant Pharma (VRX) Tops Q4 EPS by 5c; Guides In-Line
February 28, 2017 7:04 AM ESTValeant Pharma (NYSE: VRX) reported Q4 EPS of $1.26, $0.05 better than the analyst estimate of $1.21. Revenue for the quarter came in at $2.4 billion versus the consensus estimate of $2.34 billion.
GUIDANCE:
Valeant Pharma sees FY2017 revenue of $8.9-9.1 billion, versus the consensus of $8.97 billion.
Adjusted EBITDA (non-GAAP) in the range of $3.55 billion - $3.70 billion
"Today, we announced financial results that delivered on expectations and demonstrated our... More
